An RNA Splicing System that Excises Transposons from Animal mRNAs
محفوظ في:
| الحاوية / القاعدة: | bioRxiv (Feb 17, 2025) |
|---|---|
| المؤلف الرئيسي: | |
| مؤلفون آخرون: | , , , |
| منشور في: |
Cold Spring Harbor Laboratory Press
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | Citation/Abstract Full text outside of ProQuest |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3167782959 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2692-8205 | ||
| 024 | 7 | |a 10.1101/2025.02.14.638102 |2 doi | |
| 035 | |a 3167782959 | ||
| 045 | 0 | |b d20250217 | |
| 100 | 1 | |a Long-Wen, Zhao | |
| 245 | 1 | |a An RNA Splicing System that Excises Transposons from Animal mRNAs | |
| 260 | |b Cold Spring Harbor Laboratory Press |c Feb 17, 2025 | ||
| 513 | |a Working Paper | ||
| 520 | 3 | |a All genomes harbor mobile genetic parasites called transposable elements (TEs). Here we describe a system, which we term SOS splicing, that protects C. elegans and human genes from DNA transposon-mediated disruption by excising these TEs from host mRNAs. SOS splicing, which operates independently of the spliceosome, is a pattern recognition system triggered by base-pairing of inverted terminal repeat elements, which are a defining feature of the DNA transposons. We identify three factors required for SOS splicing in both C. elegans and human cells; AKAP17A, which binds TE-containing mRNAs; the RNA ligase RTCB; and CAAP1, which bridges RTCB and AKAP17A, allowing RTCB to ligate mRNA fragments generated by TE excision. We propose that SOS splicing is a novel, conserved, and RNA structure-directed mode of mRNA splicing and that one function of SOS splicing is to genetically buffer animals from the deleterious effects of TE-mediated gene perturbation.Competing Interest StatementS.J.E. is a founder of TSCAN Therapeutics, MAZE Therapeutics, ImmuneID, and Mirimus, serves on the scientific advisory boards of Homology Medicines, ImmuneID, MAZE Therapeutics, X-Chem, and TSCAN Therapeutics, and is an advisor for MPM Capital. Other authors declare no competing interests. | |
| 653 | |a Transposons | ||
| 653 | |a Structure-function relationships | ||
| 653 | |a mRNA | ||
| 653 | |a Splicing | ||
| 653 | |a RNA ligase | ||
| 653 | |a Homology | ||
| 653 | |a Pattern recognition | ||
| 653 | |a Pattern recognition systems | ||
| 700 | 1 | |a Nardone, Christopher | |
| 700 | 1 | |a Paulo, Joao A | |
| 700 | 1 | |a Elledge, Stephen | |
| 700 | 1 | |a Kennedy, Scott | |
| 773 | 0 | |t bioRxiv |g (Feb 17, 2025) | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3167782959/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full text outside of ProQuest |u https://www.biorxiv.org/content/10.1101/2025.02.14.638102v1 |